Investor · 1 deal
Every published round ATP Innovations took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Elastagen Pty Ltd | Series B | Jan 2016 | $13m | Participant | GBS Ventures, Brandon Capital portfolio |
Companies ATP Innovations has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Elastagen Pty Ltd | Jan 2016, Series B | 1 | 0 |
Fund closes reported for ATP Innovations, as distinct from the investments it has made.
Companies ATP Innovations has backed that another company then bought. An exit for the holding, not a deal ATP Innovations did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| Elastagen Pty Ltd | Allergan plc | Acquisition | 7 Feb 2018 | $350m |
Stories naming ATP Innovations. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sydney clinical-stage medical company Elastagen closed a A$13 million Series B, adding KIP, AMOREPACIFIC Ventures and Wellcome Trust to its existing backers; KIP's Sangwoo Lee joined the board.
Sydney medical device company Elastagen completed a first-in-human study of its synthetic elastin skin products and plans two further trials, targeting a European launch in early 2013.